ENTITY
Eris Lifesciences

Eris Lifesciences (ERIS IN)

65
Analysis
Health Care • India
Eris Lifesciences Limited manufactures, markets, and sells generic drugs. The Company focuses on cardiology, diabetology, endocrinology, gastroenterology, ENT, orthopedics, pediatrics, and gynecology segments. Eris Lifesciences distributes pharmaceutical drugs throughout India. v
more
•10 Jul 2025 19:45•Broker

Pharma and Healthcare: Q1FY26: Steady Revenues, Margins Under Pressure

he India Pharma and Healthcare sector is expected to see steady revenue growth. However, EBITDA margins are expected to show a decline for Q1FY26E

Logo
224 Views
Share
•21 May 2025 04:56•Broker

HSIE Results Daily: Amber Enterprises, Eris Lifesciences, Kalpataru Projects International

Amber Enterprises: Amber’s Q4FY25 revenue grew by 34% YoY to INR 37.54bn, mainly led by robust growth in consumer durables and electronics segments...

Logo
304 Views
Share
•14 May 2025 19:34•Broker

Pharmaceuticals: US to cut Rx drug price, no impact on generics

The US president Donald Trump signed an “Executive Order” (EO) to bring the prices for prescription (Rx) drugs in line with other developed nations

Logo
163 Views
Share
•04 Apr 2025 05:28•Broker

Pharmaceuticals: Pharma dodges first round of US tariff risk

The US government under Trump 2.0 has announced reciprocal tariffs across countries, including ~26% tariff on imports from India

Logo
213 Views
Share
•06 Feb 2025 06:19•Broker

HSIE Results Daily: Asian Paints, Godrej Properties, KEC International, Eris Lifesciences

The decorative and industrial business collectively clocked 1.7% volume growth and 6.6% decline in value growth in Q3 (decorative value/value...

Logo
235 Views
Share
x